Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response
Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX®; Merck Sharp and Dohme Research Laboratories) containing ∼1000 to 1625 plaque-forming units/dose during clinical trials conducted fr...
Gespeichert in:
| Veröffentlicht in: | The Pediatric infectious disease journal 1992-01, Vol.11 (1), p.19-22 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 22 |
|---|---|
| container_issue | 1 |
| container_start_page | 19 |
| container_title | The Pediatric infectious disease journal |
| container_volume | 11 |
| creator | WHITE, C JO KUTER, BARBARA J NGAI, ANGELA HILDEBRAND, CAROL S ISGANITIS, KATHRYN L PATTERSON, CAROLYN M CAPRA, ANGELA MILLER, WILLIAM J KRAH, DAVID L PROVOST, PHILIP J ELLIS, RONALD W CALANDRA, GARY B |
| description | Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX®; Merck Sharp and Dohme Research Laboratories) containing ∼1000 to 1625 plaque-forming units/dose during clinical trials conducted from 1987 to 1989. Clinical follow-up of vaccinees revealed that 2.1 and 2.4% of vaccinees developed modified cases of varicella in the first and second years, respectively, after vaccination. Most of those who developed varicella postvaccination had an attenuated illness, characterized by fewer lesions and a lower incidence of fever (≥100°F, oral) than after natural infection. The likelihood of developing varicella postvaccination decreased (P < 0.0001) as the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer increased. In addition the number of lesions in these cases tended to decrease (P = 0.07 for Year 1 and P = 0.02 for Year 2) as the 6-week glycoprotein-based enzyme-linked immunosorbent assay titer increased. Thus the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer can be used as a surrogate marker for protection from natural disease. |
| doi_str_mv | 10.1097/00006454-199201000-00006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16636609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16636609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3296-ec7670da9934bfa6577bc30f962de96a969d8a954d912f00df9283ac7d71c2453</originalsourceid><addsrcrecordid>eNp1kU9vGyEQxVHUKnXSfIRKHKLetoWFhZ3coij9I6XqpT0jDINMsl5cWMfJtw_2uumpXODNvIGnH4RQzj5xBvozq0vJTjYcoGW8quZQOiEL3om2YdDrN2TBeuCNUKp_R85Kua8OITk7Jadc8FYzuSD3P5KPIaKnzhYsNAXqVtE94LhJT9SGCTN9tDk6HAZbT87F0U4xjVfUpZxxOIj92CanCd1B7eK0onac4jL5Z5qxbNJY8D15G-xQ8OK4n5PfX25_3Xxr7n5-_X5zfdc40YJq0GmlmbcAQi6DVZ3WSydYANV6BGVBge8tdNIDbwNjPkDbC-u019y1shPn5ON8b030Z4tlMutYDvlHTNtiuFIVCYNq7Gejy6mUjMFsclzb_Gw4M3vM5i9m84p5LtXRD8c3tss1-n-DM9favzz2bXF2CNmOLpZXWyc5dHofVc62XRoq6fIwbHeYzQrtMK3M_z5ZvAAzSJXP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16636609</pqid></control><display><type>article</type><title>Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>WHITE, C JO ; KUTER, BARBARA J ; NGAI, ANGELA ; HILDEBRAND, CAROL S ; ISGANITIS, KATHRYN L ; PATTERSON, CAROLYN M ; CAPRA, ANGELA ; MILLER, WILLIAM J ; KRAH, DAVID L ; PROVOST, PHILIP J ; ELLIS, RONALD W ; CALANDRA, GARY B</creator><creatorcontrib>WHITE, C JO ; KUTER, BARBARA J ; NGAI, ANGELA ; HILDEBRAND, CAROL S ; ISGANITIS, KATHRYN L ; PATTERSON, CAROLYN M ; CAPRA, ANGELA ; MILLER, WILLIAM J ; KRAH, DAVID L ; PROVOST, PHILIP J ; ELLIS, RONALD W ; CALANDRA, GARY B</creatorcontrib><description>Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX®; Merck Sharp and Dohme Research Laboratories) containing ∼1000 to 1625 plaque-forming units/dose during clinical trials conducted from 1987 to 1989. Clinical follow-up of vaccinees revealed that 2.1 and 2.4% of vaccinees developed modified cases of varicella in the first and second years, respectively, after vaccination. Most of those who developed varicella postvaccination had an attenuated illness, characterized by fewer lesions and a lower incidence of fever (≥100°F, oral) than after natural infection. The likelihood of developing varicella postvaccination decreased (P < 0.0001) as the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer increased. In addition the number of lesions in these cases tended to decrease (P = 0.07 for Year 1 and P = 0.02 for Year 2) as the 6-week glycoprotein-based enzyme-linked immunosorbent assay titer increased. Thus the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer can be used as a surrogate marker for protection from natural disease.</description><identifier>ISSN: 0891-3668</identifier><identifier>EISSN: 1532-0987</identifier><identifier>DOI: 10.1097/00006454-199201000-00006</identifier><identifier>PMID: 1312704</identifier><identifier>CODEN: PIDJEV</identifier><language>eng</language><publisher>Baltimore, MD: Williams & Wilkins</publisher><subject>Adolescent ; Antibodies, Viral - biosynthesis ; Biological and medical sciences ; Chickenpox - immunology ; Chickenpox - prevention & control ; Chickenpox Vaccine ; Child ; Child, Preschool ; Herpesvirus 3, Human - immunology ; Humans ; Infant ; Infectious diseases ; Medical sciences ; Viral diseases ; Viral Vaccines - immunology</subject><ispartof>The Pediatric infectious disease journal, 1992-01, Vol.11 (1), p.19-22</ispartof><rights>Williams & Wilkins 1992. All Rights Reserved.</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5419575$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1312704$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WHITE, C JO</creatorcontrib><creatorcontrib>KUTER, BARBARA J</creatorcontrib><creatorcontrib>NGAI, ANGELA</creatorcontrib><creatorcontrib>HILDEBRAND, CAROL S</creatorcontrib><creatorcontrib>ISGANITIS, KATHRYN L</creatorcontrib><creatorcontrib>PATTERSON, CAROLYN M</creatorcontrib><creatorcontrib>CAPRA, ANGELA</creatorcontrib><creatorcontrib>MILLER, WILLIAM J</creatorcontrib><creatorcontrib>KRAH, DAVID L</creatorcontrib><creatorcontrib>PROVOST, PHILIP J</creatorcontrib><creatorcontrib>ELLIS, RONALD W</creatorcontrib><creatorcontrib>CALANDRA, GARY B</creatorcontrib><title>Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response</title><title>The Pediatric infectious disease journal</title><addtitle>Pediatr Infect Dis J</addtitle><description>Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX®; Merck Sharp and Dohme Research Laboratories) containing ∼1000 to 1625 plaque-forming units/dose during clinical trials conducted from 1987 to 1989. Clinical follow-up of vaccinees revealed that 2.1 and 2.4% of vaccinees developed modified cases of varicella in the first and second years, respectively, after vaccination. Most of those who developed varicella postvaccination had an attenuated illness, characterized by fewer lesions and a lower incidence of fever (≥100°F, oral) than after natural infection. The likelihood of developing varicella postvaccination decreased (P < 0.0001) as the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer increased. In addition the number of lesions in these cases tended to decrease (P = 0.07 for Year 1 and P = 0.02 for Year 2) as the 6-week glycoprotein-based enzyme-linked immunosorbent assay titer increased. Thus the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer can be used as a surrogate marker for protection from natural disease.</description><subject>Adolescent</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Chickenpox - immunology</subject><subject>Chickenpox - prevention & control</subject><subject>Chickenpox Vaccine</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Herpesvirus 3, Human - immunology</subject><subject>Humans</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Viral diseases</subject><subject>Viral Vaccines - immunology</subject><issn>0891-3668</issn><issn>1532-0987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9vGyEQxVHUKnXSfIRKHKLetoWFhZ3coij9I6XqpT0jDINMsl5cWMfJtw_2uumpXODNvIGnH4RQzj5xBvozq0vJTjYcoGW8quZQOiEL3om2YdDrN2TBeuCNUKp_R85Kua8OITk7Jadc8FYzuSD3P5KPIaKnzhYsNAXqVtE94LhJT9SGCTN9tDk6HAZbT87F0U4xjVfUpZxxOIj92CanCd1B7eK0onac4jL5Z5qxbNJY8D15G-xQ8OK4n5PfX25_3Xxr7n5-_X5zfdc40YJq0GmlmbcAQi6DVZ3WSydYANV6BGVBge8tdNIDbwNjPkDbC-u019y1shPn5ON8b030Z4tlMutYDvlHTNtiuFIVCYNq7Gejy6mUjMFsclzb_Gw4M3vM5i9m84p5LtXRD8c3tss1-n-DM9favzz2bXF2CNmOLpZXWyc5dHofVc62XRoq6fIwbHeYzQrtMK3M_z5ZvAAzSJXP</recordid><startdate>199201</startdate><enddate>199201</enddate><creator>WHITE, C JO</creator><creator>KUTER, BARBARA J</creator><creator>NGAI, ANGELA</creator><creator>HILDEBRAND, CAROL S</creator><creator>ISGANITIS, KATHRYN L</creator><creator>PATTERSON, CAROLYN M</creator><creator>CAPRA, ANGELA</creator><creator>MILLER, WILLIAM J</creator><creator>KRAH, DAVID L</creator><creator>PROVOST, PHILIP J</creator><creator>ELLIS, RONALD W</creator><creator>CALANDRA, GARY B</creator><general>Williams & Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>199201</creationdate><title>Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response</title><author>WHITE, C JO ; KUTER, BARBARA J ; NGAI, ANGELA ; HILDEBRAND, CAROL S ; ISGANITIS, KATHRYN L ; PATTERSON, CAROLYN M ; CAPRA, ANGELA ; MILLER, WILLIAM J ; KRAH, DAVID L ; PROVOST, PHILIP J ; ELLIS, RONALD W ; CALANDRA, GARY B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3296-ec7670da9934bfa6577bc30f962de96a969d8a954d912f00df9283ac7d71c2453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Chickenpox - immunology</topic><topic>Chickenpox - prevention & control</topic><topic>Chickenpox Vaccine</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Herpesvirus 3, Human - immunology</topic><topic>Humans</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Viral diseases</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WHITE, C JO</creatorcontrib><creatorcontrib>KUTER, BARBARA J</creatorcontrib><creatorcontrib>NGAI, ANGELA</creatorcontrib><creatorcontrib>HILDEBRAND, CAROL S</creatorcontrib><creatorcontrib>ISGANITIS, KATHRYN L</creatorcontrib><creatorcontrib>PATTERSON, CAROLYN M</creatorcontrib><creatorcontrib>CAPRA, ANGELA</creatorcontrib><creatorcontrib>MILLER, WILLIAM J</creatorcontrib><creatorcontrib>KRAH, DAVID L</creatorcontrib><creatorcontrib>PROVOST, PHILIP J</creatorcontrib><creatorcontrib>ELLIS, RONALD W</creatorcontrib><creatorcontrib>CALANDRA, GARY B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The Pediatric infectious disease journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WHITE, C JO</au><au>KUTER, BARBARA J</au><au>NGAI, ANGELA</au><au>HILDEBRAND, CAROL S</au><au>ISGANITIS, KATHRYN L</au><au>PATTERSON, CAROLYN M</au><au>CAPRA, ANGELA</au><au>MILLER, WILLIAM J</au><au>KRAH, DAVID L</au><au>PROVOST, PHILIP J</au><au>ELLIS, RONALD W</au><au>CALANDRA, GARY B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response</atitle><jtitle>The Pediatric infectious disease journal</jtitle><addtitle>Pediatr Infect Dis J</addtitle><date>1992-01</date><risdate>1992</risdate><volume>11</volume><issue>1</issue><spage>19</spage><epage>22</epage><pages>19-22</pages><issn>0891-3668</issn><eissn>1532-0987</eissn><coden>PIDJEV</coden><abstract>Four thousand forty-two healthy children and adolescents, ages 12 months to 17 years, were vaccinated with a single dose of live attenuated varicella vaccine (VARIVAX®; Merck Sharp and Dohme Research Laboratories) containing ∼1000 to 1625 plaque-forming units/dose during clinical trials conducted from 1987 to 1989. Clinical follow-up of vaccinees revealed that 2.1 and 2.4% of vaccinees developed modified cases of varicella in the first and second years, respectively, after vaccination. Most of those who developed varicella postvaccination had an attenuated illness, characterized by fewer lesions and a lower incidence of fever (≥100°F, oral) than after natural infection. The likelihood of developing varicella postvaccination decreased (P < 0.0001) as the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer increased. In addition the number of lesions in these cases tended to decrease (P = 0.07 for Year 1 and P = 0.02 for Year 2) as the 6-week glycoprotein-based enzyme-linked immunosorbent assay titer increased. Thus the 6-week postvaccination glycoprotein-based enzyme-linked immunosorbent assay titer can be used as a surrogate marker for protection from natural disease.</abstract><cop>Baltimore, MD</cop><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Williams & Wilkins</pub><pmid>1312704</pmid><doi>10.1097/00006454-199201000-00006</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-3668 |
| ispartof | The Pediatric infectious disease journal, 1992-01, Vol.11 (1), p.19-22 |
| issn | 0891-3668 1532-0987 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16636609 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Antibodies, Viral - biosynthesis Biological and medical sciences Chickenpox - immunology Chickenpox - prevention & control Chickenpox Vaccine Child Child, Preschool Herpesvirus 3, Human - immunology Humans Infant Infectious diseases Medical sciences Viral diseases Viral Vaccines - immunology |
| title | Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T23%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modified%20cases%20of%20chickenpox%20after%20varicella%20vaccination:%20correlation%20of%20protection%20with%20antibody%20response&rft.jtitle=The%20Pediatric%20infectious%20disease%20journal&rft.au=WHITE,%20C%20JO&rft.date=1992-01&rft.volume=11&rft.issue=1&rft.spage=19&rft.epage=22&rft.pages=19-22&rft.issn=0891-3668&rft.eissn=1532-0987&rft.coden=PIDJEV&rft_id=info:doi/10.1097/00006454-199201000-00006&rft_dat=%3Cproquest_cross%3E16636609%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16636609&rft_id=info:pmid/1312704&rfr_iscdi=true |